What is the official website of GenRx Pharmacy ?

The official website of GenRx Pharmacy is https://genrx2u.com.

What is GenRx Pharmacy's cybersecurity risk score?

GenRx Pharmacy has an AI-generated cybersecurity risk score of 685 out of 1000, indicating a Weak security posture according to Rankiteo's assessment.

How many security incidents has GenRx Pharmacy experienced?

According to Rankiteo, GenRx Pharmacy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has GenRx Pharmacy been affected by any supply chain cyber incidents ?

According to Rankiteo, GenRx Pharmacy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does GenRx Pharmacy have SOC 2 Type 1 certification ?

According to Rankiteo, GenRx Pharmacy is not certified under SOC 2 Type 1.

Does GenRx Pharmacy have SOC 2 Type 2 certification ?

According to Rankiteo, GenRx Pharmacy does not hold a SOC 2 Type 2 certification.

Does GenRx Pharmacy comply with GDPR ?

According to Rankiteo, GenRx Pharmacy is not listed as GDPR compliant.

Does GenRx Pharmacy have PCI DSS certification ?

According to Rankiteo, GenRx Pharmacy does not currently maintain PCI DSS compliance.

Does GenRx Pharmacy comply with HIPAA ?

According to Rankiteo, GenRx Pharmacy is not compliant with HIPAA regulations.

Does GenRx Pharmacy have ISO 27001 certification ?

According to Rankiteo,GenRx Pharmacy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does GenRx Pharmacy operate in ?

GenRx Pharmacy operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does GenRx Pharmacy have ?

GenRx Pharmacy employs approximately 34 people worldwide.

Does GenRx Pharmacy own any subsidiaries ?

GenRx Pharmacy presently has no subsidiaries across any sectors.

How many LinkedIn followers does GenRx Pharmacy have ?

GenRx Pharmacy's official LinkedIn profile has approximately 657 followers.

What is the NAICS classification code for GenRx Pharmacy ?

GenRx Pharmacy is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does GenRx Pharmacy have a Crunchbase profile ?

No, GenRx Pharmacy does not have a profile on Crunchbase.

Does GenRx Pharmacy have a LinkedIn profile ?

Yes, GenRx Pharmacy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/genrx-pharmacy.

How many cybersecurity incidents has GenRx Pharmacy experienced ?

As of September 10, 2026, Rankiteo reports that GenRx Pharmacy has experienced 2 cybersecurity incidents.

How many peer or competitor companies does GenRx Pharmacy have ?

GenRx Pharmacy has an estimated 5,760 peer or competitor companies worldwide.

What types of cybersecurity incidents has GenRx Pharmacy faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Ransomware.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

GenRx Pharmacy

Boost Score +25 with badge (5 left)

685

/1000

Weak

710

/1000

Moderate

GenRx Pharmacy Vendor Cyber Rating & Cyber Score

genrx2u.com

Add Your Compliance Badge

GenRx is a family owned pharmacy with two locations in Scottsdale, AZ. Opening in 2014 with a focus on dermatology. GenRx is a proven leader in the industry whose mission is to provide safe, high quality pharmacy services; excellent customer service; and clinical education to our patients in a cost-effective manner.

GenRx Pharmacy

GenRx Pharmacy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

GenRx Pharmacy

Ransomware

12/2020

GEN202117222

GenRx Pharmacy

Ransomware

100

9/2020

GEN406072825

Loading…

A.I.

GenRx Pharmacy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for GenRx Pharmacy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for GenRx Pharmacy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for GenRx Pharmacy in 2026.

Incident Types GenRx Pharmacy vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for GenRx Pharmacy in 2026.

Incident History - GenRx Pharmacy (X = Date, Y = Severity)

Loading…

SUBSIDIARY

GenRx Pharmacy Subsidiaries

Parent Company

GenRx Pharmacy

Pharmaceutical Manufacturing

Website: https://genrx2u.com

Company Size: 201-500 employees

No subsidiary data available for this company.

Loading…

GenRx Pharmacy Similar Companies

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Loading…

NEWS

GenRx Pharmacy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 01, 2021 04:06 AM

Top Ransomware Attacks

Here, we review some of the most recent ransomware attacks 2020, from January through to December.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-87924

SUMMARY

A security vulnerability has been detected in Rizwan17 inventory-management-system up to bfe78a330d01bb26b9daec5dc9ecd5c77900e03f. This affects an unknown part of the file includes/invoice_bill.php of the component Invoice Generation. Such manipulation of the argument order_date/invoice_no leads to missing authentication. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. This product takes the approach of rolling releases to provide continious delivery. Therefore, version details for affected and updated releases are not available. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: 6.5)

cvss2

Base Score: 6.4

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:P

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-87923

SUMMARY

A weakness has been identified in Rizwan17 inventory-management-system up to bfe78a330d01bb26b9daec5dc9ecd5c77900e03f. Affected by this issue is some unknown functionality of the file includes/DBOperation.php of the component List Handler. This manipulation of the argument category_name/brand_name/product_name causes cross site scripting. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. This product is using a rolling release to provide continious delivery. Therefore, no version details for affected nor updated releases are available. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-71809

SUMMARY

Authentication Bypass via Hardcoded Master Verification Code vulnerability in Siam Ordering (siam-server) 1.0.0 allows remote unauthenticated attackers to log in as any user, merchant, or administrator.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/W000i/vuln/issues/11

CVE-2026-15460

SUMMARY

The Bluetooth Classic (BR/EDR) L2CAP receive handler bt_l2cap_br_recv() in subsys/bluetooth/host/classic/l2cap_br.c dispatched inbound data PDUs based only on the destination channel ID, without checking that the target channel had reached the BT_L2CAP_CONNECTED state. A dynamic channel is assigned its RX CID and added to the connection's channel list while still in BT_L2CAP_CONNECTING (and later BT_L2CAP_CONFIG) — before configuration completes and, for PSMs that require security, before the peer is authenticated (l2cap_br_conn_req()). Because the channel is already findable by bt_l2cap_br_lookup_rx_cid() during this window, a remote peer within radio range can send a data PDU addressed to that CID and have it processed on a not-yet-established channel. The dispatch keys off channel fields (BR_CHAN(chan)->rx.mode, rx.mps) that are only initialized during configuration by l2cap_br_conf(); since channel objects are pooled and bt_l2cap_br_chan_del() does not reset rx.mode or the reassembly buffer _sdu, a reused channel can carry stale state into the CONNECTING window and route the frame into the retransmission/flow-control path (bt_l2cap_br_ret_fc_recv()) with stale parameters and a possibly stale _sdu pointer. The impact is delivery of attacker data to upper-layer protocol handlers on a half-open (and possibly unauthenticated) channel, plus operation on stale or partially initialized channel state on reused channel objects — leading to channel/link teardown (denial of service) and, in the stale-_sdu case, a dangling-pointer condition. The fix adds an explicit BR_CHAN(chan)->state < BT_L2CAP_CONNECTED guard that drops any data received before the channel is fully connected.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

Impact Score

2.5

Exploitability

2.8

REFERENCES

CVE-2026-88069

SUMMARY

Pandora contains a path traversal vulnerability in its archive extraction worker. When processing a specially crafted archive or disk image, attacker-controlled file paths could be used without ensuring that the resulting destination remained within the intended extraction directory. An attacker able to submit a malicious file for analysis could use path traversal sequences or crafted paths to cause extracted content to be written outside the designated extraction directory, potentially overwriting files accessible to the Pandora worker process. Successful exploitation could result in unauthorized modification of application or system files, denial of service, and potentially further compromise depending on the permissions of the Pandora process and the files that can be overwritten. The vulnerability is addressed by resolving each extraction destination path before writing and verifying that it remains below the expected extraction directory. Extraction attempts resolving outside this directory are rejected and reported as path traversal attempts.

Published

Date2026-09-09

Updated

Date2026-09-09

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:H/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/pandora-analysis/pandora/commit/d86ac5b260fb9a41e07f1da1bbd326cdcfc188a7

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

GenRx Pharmacy Vendor Cyber Rating & Cyber Score

GenRx Pharmacy A.I CyberSecurity Scoring

GenRx Pharmacy CyberSecurity News & History

GenRx Pharmacy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for GenRx Pharmacy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types GenRx Pharmacy vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - GenRx Pharmacy (X = Date, Y = Severity)

GenRx Pharmacy Subsidiaries

Parent Company

GenRx Pharmacy

GenRx Pharmacy Similar Companies

Ipca Laboratories Limited

PT Kalbe Farma, Tbk

Astellas Pharma

AbbVie

Lupin

SUN PHARMA

Sanofi

Novo Nordisk

Alkem Laboratories Ltd.

GenRx Pharmacy CyberSecurity News

Top Ransomware Attacks

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

GenRx Pharmacy CyberSecurity News & History

GenRx Pharmacy Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for GenRx Pharmacy

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types GenRx Pharmacy vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - GenRx Pharmacy (X = Date, Y = Severity)

GenRx Pharmacy Subsidiaries

Parent Company

GenRx Pharmacy

GenRx Pharmacy Similar Companies

Ipca Laboratories Limited

PT Kalbe Farma, Tbk

Astellas Pharma

AbbVie

Lupin

SUN PHARMA

Sanofi

Novo Nordisk

Alkem Laboratories Ltd.

GenRx Pharmacy CyberSecurity News

Top Ransomware Attacks

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo